Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction

Conclusions: In seven of the eight patients, SCIG gave improved tolerability and patient satisfaction with similar efficacy compared with IVIG.

http://tan.sagepub.com/cgi/content/abstract/8/1/14?rss=1

Source: Therapeutic Advances in Neurological Disorders - January 6, 2015 Category: Neurology Authors: Hadden, R. D. M., Marreno, F. Tags: Original Research Source Type: research